Literature DB >> 33893158

How Accurately does PSMA Inhibitor 18F-DCFPyL-PET-CT Image Prostate Cancer?

Lawrence D True1, Delphine L Chen2.   

Abstract

Current techniques for imaging prostate cancer (CT, MRI, and PET agents 18F-fluorodeoxyglucose, 11C-choline, 11C-acetate, and 18F-fluciclovine) are limited in sensitivity and specificity. PSMA PET agent 68Ga-PSMA-11 has recently been approved by the FDA. We comment on the performance of novel PSMA agent 18F-DCFPyL-PET/CT.See related article by Morris et al., p. 3674. ©2021 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33893158      PMCID： PMC8254752          DOI： 10.1158/1078-0432.CCR-21-0749

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

Review 1.  Prostate cancer-specific PET radiotracers: A review on the clinical utility in recurrent disease.

Authors:  Jaden D Evans; Krishan R Jethwa; Piet Ost; Scott Williams; Eugene D Kwon; Val J Lowe; Brian J Davis
Journal:  Pract Radiat Oncol       Date:  2017-07-20

2.  Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues.

Authors:  G L Wright; C Haley; M L Beckett; P F Schellhammer
Journal:  Urol Oncol       Date:  1995 Jan-Feb       Impact factor: 3.498

Review 3.  Role of metabolic imaging in diagnosis of primary, metastatic, and recurrent prostate cancer.

Authors:  Mohammad Amin Hadavand; Dirk Mayer; Wengen Chen; Amelia Wnorowski; Mohummad Minhaj Siddiqui
Journal:  Curr Opin Oncol       Date:  2020-05       Impact factor: 3.645

Review 4.  PSMA-targeted Radiotracers versus 18F Fluciclovine for the Detection of Prostate Cancer Biochemical Recurrence after Definitive Therapy: A Systematic Review and Meta-Analysis.

Authors:  Nelly Tan; Udochukwu Oyoyo; Niusha Bavadian; Nicholas Ferguson; Anudeep Mukkamala; Jeremie Calais; Matthew S Davenport
Journal:  Radiology       Date:  2020-05-12       Impact factor: 11.105

5.  Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study.

Authors:  Michael J Morris; Steven P Rowe; Michael A Gorin; Lawrence Saperstein; Frédéric Pouliot; David Josephson; Jeffrey Y C Wong; Austin R Pantel; Steve Y Cho; Kenneth L Gage; Morand Piert; Andrei Iagaru; Janet H Pollard; Vivien Wong; Jessica Jensen; Tess Lin; Nancy Stambler; Peter R Carroll; Barry A Siegel
Journal:  Clin Cancer Res       Date:  2021-02-23       Impact factor: 13.801
  5 in total
  1 in total

1.  The performance of 18F-PSMA PET/CT in the detection of prostate cancer: a systematic review and meta-analysis.

Authors:  Zhi-Qiang Qin; Gao-Jian Pan; Zheng Xu; Hao Wang; Lu-Wei Xu; Rui-Peng Jia
Journal:  Asian J Androl       Date:  2022 Jul-Aug       Impact factor: 3.054
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.